The mAb G250 (girentuximab), which was originally derived from hybridomas generated from mouse splenocytes immunized with human ccRCC, specifically recognizes an extracellular conformational epitope on the catalytic domain of CA IX. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.